Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 7, Issue 1, 2008, Pages 7-14

  Masi, Gianluca ^a   Vasile, Enrico ^a   Loupakis, Fotios ^a   Bursi, Simona ^a   Ricci, Sergio ^b   Petrini, Iacopo ^b   Fontana, Andrea ^a   Allegrini, Giacomo ^a   Falcone, Alfredo ^a,c  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

5 fluorouracil; Dose limiting toxicity; FOLFOXIRI; Leucovorin; Uracil tegafur

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; RALTITREXED; UFT;

CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTINUOUS INFUSION; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; HUMAN; LETHARGY; LIVER METASTASIS; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 39149097520     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.002     Document Type: Review

References (45)

1. Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer 2006; 95:131-8.
2. Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomised controlled trials. Br J Cancer 2000; 82:1789-94.
3. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-7.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-14.
5. Kohne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23:4856-65.
6. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 181:136-47.
7. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47.
8. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663-9.
9. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8:347-53.
10. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15:933-9.
11. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16:1311-9.
12. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
13. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209-14.
14. Fischel JL, Rostagno P, Formento P, et al. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Br J Cancer 2001; 84:579-85.
15. Souglakos J, Mavroudis D, Kakolyris S, et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 2002; 20:2651-7.
16. Ychou M, Conroy T, Seitz JF, et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumours. Ann Oncol 2003; 14:481-9.
17. Calvo E, Cortes J, Rodriguez J, et al. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Clin Colorectal Cancer 2002; 2:104-10.
18. Garufi C, Bria E, Vanni B, et al. A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Br J Cancer 2003; 17:1870-5.
19. Cornella P, Casaretti R, De Rosa V, et al. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. Ann Oncol 2002; 13:1874-81.
20. Goetz MP, Erlichman C, Windebank AJ, et al. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumours. J Clin Oncol 2003; 21:3761-9.
21. Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20:4006-14.
22. Masi G, Allegrini G, Cupini S et al. First line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of phase II study with a simplified biweekly schedule. Ann Oncol 2004; 15:1766-72.
23. Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/ folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 2006; 13:58-65.
24. Quenet F, Nordlinger B, Rivoire M, et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (FOLFIRINOX): a prospective phase II trial. Proc Am Soc Clin Oncol 2004; 23:273 (Abstract 3613)
25. Lee J, Kang WK, Kwon JM, et al. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol 2007; 18:88-92.
26. Conroy T, Paillot B, Francois E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer - a Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 23:1228-36.
27. Ychou M, Desseigne F, Guimbaud R, et al. Randomized phase II trial comparing FOLFIRINOX (5FU/leucovorin, irinotecan and oxaliplatin) vs gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. First results of the ACCORD 11/0402 trial. J Clin Oncol 2007; 25(18 suppl):201s (Abstract 4516).
28. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3605-16.
29. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-106.
30. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:2084-91
31. Park SH, Bang SM, Cho EK, et al. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology 2004; 66:353-7.
32. Bajetta E, Di Bartolomeo M, Buzzoni R, et al. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer 2007; 96:439-44.
33. Maroun J, Jonker DJ, Cripps C, et al. Encouraging results from a phase I study of capecitabine (X), irinotecan (I), and oxaliplatin (O) as first-line therapy in patients (pts) with advanced or metastatic colorectal cancer (mCRC): phase I study findings. J Clin Oncol 2007; 25(18 suppl):185s (Abstract 4086).
34. Samantas E, Rigatos SK, Triantafillis M, et al. Phase I dose-finding study of capecitabine (X) with escalating irinotecan (I) and oxaliplatin (O) in patients (pts) with previously treated solid tumors. J Clin Oncol 2005; 23(18 suppl):256s (Abstract 3543).
35. Krishnamurthi SS, Brell JM, Coviello KM, et al. Phase I study of oxaliplatin (Ox), irinotecan (Irino), and capecitabine (Cape) in patients with solid tumors. Proc Am Soc Clin Oncol 2004; 23:154 (Abstract 2111).
36. Pavia OA, Cangiano J, Crisostomo R, et al. Phase II study of oxaliplatin, capecitabine, and irinotecan (OCI) in patients (pts) with previously untreated colorectal cancer (crc). J Clin Oncol 2005; 23(18 suppl):307s (Abstract 3746).
37. Petrovic Z. Oxaliplatin plus irinotecan and capecitabine as second line chemotherapy in patients with advanced colorectal carcinoma. Presented at: the 2005 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, Florida. Abstract 271.
38. Buzzoni R, Bajetta E, Di Bartolomeo M, et al. COI regimen (capecitabine, oxaliplatin, irinotecan) as possible neoajuvant treatment in metastatic colorectal cancer patients. Ann Oncol 2006; 17: S11 (Abstract D1).
39. Masi G, Bursi S, Loupakis F, et al. The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (mCRC): preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (GONO). J Clin Oncol 2007; 25(18 suppl): 187s (Abstract 4096).
40. Sheikh HY, Valle JW, Palmer K, et al. Concurrent irinotecan, oxaliplatin, and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. Br J Cancer 2007; 96:38-43.
41. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment of metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670-6.
42. Falcone A, Andreuccetti M, Brunetti I, et al. Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (mCRC). J Clin Oncol 2007; 25(18 suppl):170s (Abstract 4026).
43. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94:798-805.
44. Masi G, Marcucci L, Loupakis F, et al. First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Ann Oncol 2006; 17:1249-54.
45. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIR1 versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866-75.